Table 2.
Therapeutic efficacies.
| mFOLFIRINOX (N = 27) | GOFL (N = 28) | Total (N = 55) | |
|---|---|---|---|
| Best response to ICT | |||
| Partial response | 6 (22.2%) | 4 (14.3%) | |
| Stable disease | 20 (74.1%) | 18 (64.3%) | |
| Progressive disease | 1 (3.7%) | 6 (21.4%) | |
| Disease control rate | 26 (96.3%) | 22 (78.6%) | |
| Response after CCRT | |||
| Partial response | 6 | 4 | |
| Stable disease | 7 | 11 | |
| Progressive disease | 8 | 2 | |
| Per-protocol R0/R1 resection | 1 (3.7%) | 5 (17.8%) | 6 (10.9%) |
| Median (95% CI) PFS, months | 6.6 (5.9–12.5) | 7.6 (3.9–12.3) | 6.7 (6.2–8.3) |
| 9-month PFS rate | 30.5% | 35.9% | 33.3% |
| Median (95% CI) OS, months | 19.6 (13.4–22.9) | 17.9 (13.4–23.9) | 18.7 (15.8–21.9) |
| 12-month OS rate (%) | 88.9 (69.4–96.3) | 82.1 (62.3–92.2) | 85.5 (73.0–92.4) |
| 24-month OS rate (%) | 29.6 (14.1–47.0) | 31.8 (15.7–49.1) | 30.8 (19.2–43.1) |